Zevra Therapeutics Inc. (ZVRA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $540.30M
Last updated: Nov 17, 2026 at 11:06 AM ET
Zevra Therapeutics Inc. (ZVRA) Financials: Revenue, Profit and Cash Flow
Zevra Therapeutics reported revenue of $106.47M for the fiscal year ended Dec 31, 2025, up 350.9% from the year before. That year, net income was $83.23M with a net margin of 78.2%, operating cash flow was -$1.60M and free cash flow was -$2.43M. The quarter ended Sep 30, 2026 had revenue of $37.76M and net income of $19.21M.
Revenue and Margins
The operating margin was -59.1% in the fiscal year ended Dec 2025, the lowest of the 3 years shown with an operating margin. Over the 6 years to Dec 2025, revenue grew from $12.84M, a compound annual rate of 42.3%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $106.47M | +350.9% | 84.5% | -59.1% | 78.2% |
| Dec 2024 | $23.61M | -14.0% | 68.6% | -368.5% | -446.9% |
| Dec 2023 | $27.46M | +170.3% | 92.1% | -180.6% | -167.7% |
| Dec 2022 | $10.16M | -64.5% | 97.8% | -418.9% | -263.5% |
| Dec 2021 | $28.65M | +115.6% | 92.8% | 27.0% | -29.9% |
| Dec 2020 | $13.29M | +3.5% | 100.0% | -42.2% | -96.0% |
| Dec 2019 | $12.84M | N/A | 100.0% | -158.4% | -191.0% |
| Dec 2018 | $0 | N/A | N/A | N/A | N/A |
| Dec 2017 | $0 | N/A | N/A | N/A | N/A |
| Dec 2016 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $106.47M | $23.61M | $27.46M | $10.16M | $28.65M | $13.29M | $12.84M | $0 | $0 | $0 |
| Cost of revenue | $16.48M | $7.42M | $2.17M | $222.00K | $2.06M | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $89.99M | $16.20M | $25.29M | $9.94M | $26.59M | $13.29M | $12.84M | $0 | $0 | $0 |
| Research and development | $12.74M | $42.09M | $39.81M | $37.47M | $10.16M | $8.84M | $19.41M | $41.76M | $20.59M | $20.47M |
| Operating income | -$62.94M | -$87.00M | -$49.60M | -$42.56M | $7.73M | -$5.61M | -$20.34M | -$55.90M | -$33.37M | -$37.48M |
| Net income | $83.23M | -$105.51M | -$46.05M | -$26.77M | -$8.55M | -$12.76M | -$24.52M | -$56.47M | -$43.39M | -$16.52M |
| EBITDA | $88.64M | -$79.47M | -$48.08M | -$27.04M | $8.11M | -$3.21M | -$16.38M | -$47.98M | -$32.34M | -$1.00M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $37.76M | $39.66M | $36.22M | $34.13M | $26.06M | $25.88M | $20.40M | $12.04M | $3.69M | $4.45M | $3.42M | $12.92M |
| Gross profit | $35.96M | $39.66M | $34.32M | $32.60M | $24.82M | $25.88M | $19.06M | $10.68M | $1.39M | $876.00K | $3.25M | $11.69M |
| Operating income | $11.58M | $16.78M | $52.15M | $9.31M | $4.14M | -$71.04M | -$5.36M | -$15.42M | -$27.31M | -$23.80M | -$20.49M | -$15.16M |
| Net income | $19.21M | $8.75M | $37.89M | $12.16M | -$544.00K | $74.71M | -$3.10M | -$35.74M | -$33.23M | -$19.93M | -$16.62M | -$19.89M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded total debt of $62.35M by $59.00K.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $284.73M | $178.13M | $172.33M | $115.34M | $132.94M | $11.21M | $10.51M | $26.75M | $52.46M | $84.89M |
| Current assets | $223.01M | $86.03M | $86.94M | $92.83M | $115.06M | $8.38M | $6.97M | $23.72M | $45.90M | $74.36M |
| Cash and equivalents | $62.41M | $33.78M | $43.05M | $65.47M | $112.35M | $4.21M | $3.22M | $18.41M | $10.87M | $16.76M |
| Total liabilities | $130.07M | $138.46M | $110.46M | $40.22M | $5.82M | $77.62M | $84.96M | $93.31M | $109.97M | $103.58M |
| Short-term debt | $419.00K | $420.00K | $37.70M | $0 | $371.00K | $390.00K | $0 | $3.55M | $3.52M | $157.00K |
| Long-term debt | $61.93M | $59.50M | $5.07M | $12.80M | $0 | $68.05M | $77.34M | $78.11M | $89.40M | $91.17M |
| Shareholder equity | $154.66M | $39.67M | $61.86M | $75.12M | $127.12M | -$66.41M | -$74.46M | -$66.57M | -$57.52M | -$18.70M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $313.57M | $302.71M | $278.58M | $284.73M | $270.12M | $256.28M | $172.71M | $178.13M | $191.55M | $144.41M | $151.28M | $172.33M |
| Total liabilities | $74.65M | $85.06M | $72.78M | $130.07M | $136.95M | $139.05M | $131.69M | $138.46M | $121.78M | $111.93M | $102.47M | $110.46M |
| Cash and equivalents | $122.15M | $145.32M | $95.59M | $62.41M | $54.44M | $47.71M | $37.34M | $33.78M | $54.04M | $39.26M | $42.85M | $43.05M |
| Shareholder equity | $238.92M | $217.65M | $205.80M | $154.66M | $133.16M | $117.23M | $41.02M | $39.67M | $69.77M | $32.48M | $48.82M | $61.86M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.60M | -$69.67M | -$33.53M | -$18.72M | $10.44M | -$1.94M | -$23.74M | -$54.20M | -$33.10M | -$29.77M |
| Capital expenditures | $835.00K | $0 | $296.00K | $93.00K | $102.00K | $33.00K | $26.00K | $21.00K | $181.00K | $643.00K |
| Free cash flow | -$2.43M | -$69.67M | -$33.83M | -$18.81M | $10.34M | -$1.97M | -$23.76M | -$54.22M | -$33.28M | -$30.41M |
| Dividends paid | N/A | N/A | N/A | $324.00K | $30.82M | N/A | N/A | N/A | N/A | N/A |
| Share repurchases | N/A | N/A | $3.45M | $4.72M | $1.34M | $84.00K | $0 | $184.00K | N/A | N/A |
| Investing cash flow | $18.13M | -$22.16M | -$17.39M | -$36.72M | -$15.52M | -$33.00K | $3.23M | $33.33M | $27.41M | -$45.85M |
| Financing cash flow | $12.06M | $82.11M | $28.46M | $8.35M | $113.11M | $2.74M | $4.94M | $28.02M | -$203.00K | $61.16M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $10.05M | $17.03M | $6.14M | $5.52M | $4.71M | -$3.60M | -$8.22M | -$16.25M | -$18.14M | -$19.11M | -$16.16M | -$16.16M |
| Capital expenditures | $238.00K | $217.00K | $35.00K | $31.00K | $554.00K | $213.00K | $99.00K | $0 | $0 | $0 | $0 | $72.00K |
| Free cash flow | $9.81M | $16.82M | $6.11M | $5.49M | $4.16M | -$3.81M | -$8.32M | -$16.25M | -$18.14M | -$19.11M | -$16.16M | -$16.23M |
Frequently Asked Questions About ZVRA
What is Zevra Therapeutics' annual revenue?
Zevra Therapeutics reported revenue of $106.47M for the fiscal year ended Dec 31, 2025.
How fast is Zevra Therapeutics' revenue growing?
Revenue was up 350.9% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 118.8%.
Is Zevra Therapeutics profitable?
Yes. Zevra Therapeutics reported net income of $83.23M for the fiscal year ended Dec 31, 2025, with a net margin of 78.2%.
How much free cash flow does ZVRA generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$1.60M minus capital expenditures of $835.00K produced free cash flow of -$2.43M.
How much debt does Zevra Therapeutics have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $61.93M, short-term debt of $419.00K and cash and equivalents of $62.41M.
ZVRA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors